Biologics CDMO Market Size

Biologics CDMO Market size was valued at USD 18.46 billion in 2024 and is likely to reach USD 73.38 billion by the end of 2037, registering around 11.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of biologics contract development & manufacturing organization is assessed at USD 20.11 billion.

The major factor to influence the growth of the market is the growing prevalence of chronic diseases such as diabetes. The number of diabetes patients is set to rise to about 642 million by 2030 up from a number of over 536 million in the year 2021. Further, by 2045 the number of patients is estimated to reach approximately 782 million. Hence, the demand for biologics CDMO is set to grow.

Additionally, there has been a surge in outsourcing of clinical services. While traditional underlying drivers such as the availability of specialized knowledge and technology (exacerbated by treatments being more complex), cost advantages, and a greater focus on marketing and innovation among big. Pharma remains strong, but significant recent developments have occurred that strengthen the need for outsourcing investment. Some of these recent developments include automation, the Internet of Things (IoT), software development, and other contemporary technologies. However, this technology needs to be updated recurrently which is why the demand for outsourcing is growing. Hence, the market revenue for biologics CDMO is poised to rise.